News & Announcements
PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies targeting eIF4E, today announced it will present pre-clinical data on the company’s eIF4E program for ER+ breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans, LA.
NATICK, MA – August 12, 2020 – PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation, today announced the appointment of Katherine Bowdish, Ph.D., as its President and Chief Executive Officer. Dr. Bowdish will also join the Board of Directors of PIC.
BOSTON--(BUSINESS WIRE)--APRIL 15, 2020: PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation, closed a $5M Series Seed round of preferred equity funding.